Claudin-1
CLDN1proteinClaudin-1 loss compromises intestinal-epithelial barrier integrity, promoting lipopolysaccharide translocation and systemic inflammatory MI risk.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleTight-junction protein; intestinal barrier integrity loss drives systemic inflammation and endotoxemia in MI.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II75
A — assay feasibility68
E — evidence strength27
T1DI (composite)4
Specificity differential (R−C)-54.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- The gut microbiotas with metabolites regulate the protective role of miR-30a-5p in myocardial infarction.Journal of advanced research · 2024 · PMID 39442873 · doi